Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

40.44USD
26 Apr 2017
Change (% chg)

$-0.84 (-2.03%)
Prev Close
$41.28
Open
$40.89
Day's High
$40.89
Day's Low
$40.43
Volume
53,606
Avg. Vol
60,574
52-wk High
$54.70
52-wk Low
$39.04

RDY.N

Chart for RDY.N

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.52
Market Cap(Mil.): $6,749.25
Shares Outstanding(Mil.): 165.74
Dividend: 0.30
Yield (%): 0.74

Financials

  RDY.N Industry Sector
P/E (TTM): 44.76 29.33 30.27
EPS (TTM): 0.91 -- --
ROI: 6.99 13.69 13.24
ROE: 7.74 14.64 14.40

BRIEF-Dr. Reddy's Labs launches Ezetimibe and Simvastatin tablets in U.S. market

* Says launch of Ezetimibe and Simvastatin tablets in U.S. market Source text for Eikon: Further company coverage:

12:40am EDT

BRIEF-Fresenius sees no change in relationship of Merck KGaA's unit with partner Dr Reddy's

* Fresenius ceo sturm says we've had a good q1 but will not provide details

Apr 25 2017

BRIEF-Dr.Reddy's Laboratories announces launch of progesterone capsules in the U.S.

* Dr.Reddy's Laboratories - announces the launch ofprogesterone capsules in the U.S. market". Source text: (http://bit.ly/2pLTt0P) Further company coverage:

Apr 21 2017

Judge tosses drug packaging case against Dr. Reddy's, pharmacies

Dr. Reddy's Laboratories Ltd and three pharmacy chains have won the dismissal of a whistleblower lawsuit accusing them of fraudulently seeking federal reimbursement for drugs that were distributed in packaging not tested for child safety.

Mar 28 2017

BRIEF-Dr. Reddy's Labs, Integra Lifesciences sign deal to market Duragen products in India

* Co, Integra Lifesciences enter agreement to market, distribute Duragen plus and suturable duragen dural regeneration in India

Mar 27 2017

BRIEF-Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories

* Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market

Mar 16 2017

BRIEF-Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant

* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017

Feb 21 2017

BRIEF-Dr.Reddy's Labs says no claims against co for monetary damages

* Clarifies on news item "Dr. Reddy's announces US district court's opinion relating to patent infringement"

Feb 17 2017

BRIEF-Dr Reddy's says U.S. court finds co's product infringes some patents

* Says Dr. Reddy's Laboratories announces U.S. district court's opinion relating to patent infringement

Feb 15 2017

BRIEF-Dr.Reddy's Labs says co not served with legal papers in matter as in Mezzion's press release

* Dr.Reddy's Laboratories clarifies on news item "Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories."

Jan 27 2017

More From Around the Web

Earnings vs. Estimates